Table 1 Baseline demographics of the patients included in the study.
| Characteristic | N=20 | ||
|---|---|---|---|
| Age (years); mean±SD [range] | 33.7±10.5 [18–54] | ||
| Sex (Male/Female); n (%) | 16 (80%)/4 (20%) | ||
| Race (Caucasian); n (%) | 20 (100%)% | ||
| Tics | Age at onset (mean, years) | 6.7 | |
| Severity | YGTSS-TTS (mean±SD | 26.7±6.2 | |
| YGTSS-GS (mean±SD) | 43.6±14.6 | ||
| MRVS (mean±SD) | 12.3±3.8 | ||
| Premonitory urges | PUTS (mean±SD) | 19.8±5.6 | |
| Comorbidities | ADHD*; n (%) | 4 (20%) | |
| OCD*; n (%) | 5 (25%) | ||
| Current treatment of TS | Cannabis/cannabinoid drugs; n (%) | 11 (55%) | |
| Antipsychotics; n (%) | 6 (30%) | ||
| No pharmacological treatment | 4 (20%) | ||
*Patients were assessed for obsessive compulsive disorder (OCD) and attention deficit/hyperactivity disorder (ADHD) at the screening, and were diagnosed according to clinical judgment. MRVS: Modified Rush Video Scale, PUTS: Premonitory Urge for Tic Scale; TS: Tourette Syndrome; YGTSS: Yale Global Tic Severity Scale; YGTSS-GS: Yale Global Tic Severity Scale – Global Score; YGTSS-TTS Yale Global Tic Severity Scale -Total Tic Score.